Correvio International Sàrl Revenue and Competitors
Employee Data
- 00
Correvio International Sàrl's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Finance, EU | Reveal Email/Phone |
3 | Associate Director Regulatory Affairs | Reveal Email/Phone |
4 | Brand Manager - Europe | Reveal Email/Phone |
5 | Customer Service & Tender Manager | Reveal Email/Phone |
6 | Executive Assistant | Reveal Email/Phone |
7 | President and CFO | Reveal Email/Phone |
8 | CCO | Reveal Email/Phone |
9 | Key-accountmanager Belgium - Luxembourg | Reveal Email/Phone |
10 | Key Account Manager | Reveal Email/Phone |
Correvio International Sàrl Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Correvio International Sàrl?
About us Correvio International is a privately held pharmaceutical company located in Geneva, Switzerland. Correvio LLC, our global supply chain operation, is located in Chester, Pennsylvania, USA. Currently, we commercialise Aggrastat® (tirofiban HCl)* in more than 50 countries worldwide either directly (Europe) or via our distributor and partner network. Our aim We strive to help healthcare professionals improve outcomes for critically ill patients, currently in the field of Acute Coronary Syndromes (ACS). Our dedicated teams of employees offer considerable knowledge and experience and a shared goal of finding the right therapy for the right patient. Our product Aggrastat® is a reversible GP IIb/IIIa inhibitor for use in indicated Acute Coronary Syndrome patients. Aggrastat® is used to treat more than 250,000 patients annually and Correvio measures its business success in terms of Major Adverse Cardiac Events (MACE) prevented (approximately 18,000 MACE annually). Our services Core to our business is our multi-lingual 24/7/365 Medical Information Center and our contemporary medical education tools and services.
keywords:N/A
N/A
Total Funding
N/A
Number of Employees
N/A
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Correvio International Sàrl News
... that Endo International plc's subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sàrl...
The announcement comes after the company said Dec. 10 that the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against recommending approval, stating that the drug’s risk-benefit profile did not support its authorization. Shares of the company fell 67% on the Toronto Stock Exc ...
Other Companies in Geneva
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 1 | -67% | N/A |
#2 | $0.2M | 3 | N/A | N/A |
#3 | $0.2M | 3 | -50% | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.3M | 4 | -20% | N/A |